Edition:
India

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

3.96USD
10:14pm IST
Change (% chg)

$0.09 (+2.33%)
Prev Close
$3.87
Open
$3.83
Day's High
$3.97
Day's Low
$3.82
Volume
6,527
Avg. Vol
19,926
52-wk High
$12.09
52-wk Low
$3.10

Select another date:

Fri, Dec 22 2017

Novelion unit asks U.S. judge to approve plea deal, cites money woes

BOSTON Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case's uncertainty.

Novelion unit asks U.S. judge to approve plea deal, cites money woes

BOSTON, Dec 22 Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case's uncertainty.

BRIEF-Aspen Announces Strategic Partnership With CGB Diversified Services

* ASPEN ANNOUNCES STRATEGIC PARTNERSHIP WITH CGB DIVERSIFIED SERVICES

BRIEF-Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics

* EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING Source text : http://bit.ly/2yOFk6N Further company coverage:

BRIEF-Novelion Therapeutics Appoints Michael Price As CFO

* NOVELION THERAPEUTICS APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER

BRIEF-Novelion Therapeutics provides update on agreement between Aegerion Pharma and U.S. Department of Justice

* Novelion Therapeutics provides update on agreement between Aegerion Pharmaceuticals and U.S. Department of Justice

U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON A judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes of its marketing of a cholesterol drug, saying it was "not in the public interest."

UPDATE 1-U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON, Nov 20 A judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes of its marketing of a cholesterol drug, saying it was "not in the public interest."

U.S. judge rejects plea deal with Novelion's Aegerion

BOSTON, Nov 20 A U.S. judge on Monday rejected a plea deal that was part of Aegerion Pharmaceuticals Inc's recent agreement to pay $40.1 million to resolve U.S. probes into its marketing of a cholesterol drug, saying it was "not in the public interest."

BRIEF-Novelion Therapeutics says CEO resigns, posts Q3 results

* Novelion Therapeutics reports third quarter 2017 financial results and announces leadership change

Select another date: